UK – NICE backing for Astella’s Xospata

NICE has recommended use of Astellas' Xospata (gilteritinib) for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).

The backing, as outlined in a Final Appraisal Determination, is contingent on a commercial agreement being offered by the company and does not include its use as a maintenance therapy after haematopoietic stem cell transplant.

AML is a rare and aggressive cancer of the blood and bone marrow that, if untreated, can be fatal within a few months.

Around 3,100 people in the UK are diagnosed with AML each year, of which one-third will test positive for the FLT3 gene mutation, which can result in higher relapse rates and lower rates of survival than other forms of the disease.

The prognosis of patients with AML has remained poor despite advances in chemotherapy and little progress has been made that improves the long-term outcome for these patients…